Healthcare Sector Update

Zentalis Pharmaceuticals has presented updated clinical data for azenosertib in platinum-resistant ovarian cancer patients. The data showed promising results.

• The clinical data was presented for azenosertib, a treatment being developed for platinum-resistant ovarian cancer.
• The data demonstrated the efficacy of azenosertib in treating platinum-resistant ovarian cancer.

AbbVie has announced final analysis results from the Phase 3 MIRASOL trial for ELAHERE, a treatment for ovarian cancer. The results showed a consistent survival benefit.

• The MIRASOL trial was a Phase 3 clinical trial for ELAHERE, a treatment for ovarian cancer.
• The final analysis results showed a consistent survival benefit for patients treated with ELAHERE.

Several companies have submitted unaudited financial results. These submissions are not directly related to Cigna Group.

• The unaudited financial results have been submitted by several companies, but the specific companies and details are not provided.